Blog
RSS FeedPosted by Michael Wonder on 03 Aug 2022
Pralsetinib for treating advanced RET fusion positive non-small-cell lung cancer
3 August 2022 - NICE has published evidence-based recommendations on the use of pralsetinib (Gavreto) for the treatment of adults ...
Posted by Michael Wonder on 28 Jul 2022
Novartis’ Beovu recommended by NICE
28 July 2022 - Patients set to benefit from new treatment for sight-threatening eye condition ...
Posted by Michael Wonder on 14 Jul 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease
13 July 2022 - NICE has published evidence-based recommendations on the use of roxadustat (Evrenzo) for the treatment of adults ...
Posted by Michael Wonder on 14 Jul 2022
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
14 July 2022 - An agreement with the companies on the price of two breast cancer treatments, Piqray and Trodelvy, has ...
Posted by Michael Wonder on 13 Jul 2022
NICE terminates appraisal of belimumab for new indication
13 July 2022 - You guessed it, the sponsor decided not to lodge an evidence submission. ...
Posted by Michael Wonder on 13 Jul 2022
NICE issues final guidance on the use of risankizumab for psoriatic arthritis
13 July 2022 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of adults ...
Posted by Michael Wonder on 13 Jul 2022
NICE issues final guidance for reimbursement making Vazkepa (icosapent ethyl) available across the NHS in England & Wales
13 July 2022 - Newly published final guidance by NICE in the UK confirms its prior draft recommendation for the use ...
Posted by Michael Wonder on 08 Jul 2022
NICE recommends Opdivo as post-surgery treatment
8 July 2021 - The therapy will be used for specific muscle invasive urothelial cancer patients ...
Posted by Michael Wonder on 06 Jul 2022
NICE recommends Janssen’s treatment for active psoriatic arthritis
6 July 2022 - Clinical trial evidence suggests that Tremfya is effective when compared with a placebo ...
Posted by Michael Wonder on 06 Jul 2022
Setmelanotide for the treatment of patients with obesity caused by LEPR or POMC deficiency
6 July 2022 - NICE has issued fvidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC ...
Posted by Michael Wonder on 05 Jul 2022
NICE recommends three more treatments for atopic dermatitis
30 June 2022 - Doctors now have three more prescribing options for patients with severe atopic dermatitis who do not ...
Posted by Michael Wonder on 30 Jun 2022
Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...
Posted by Michael Wonder on 29 Jun 2022
NICE publishes its 800th technology assessment
29 June 2022 - TAs 799 and 800 are for the same technology. ...
Posted by Michael Wonder on 23 Jun 2022
NICE opts to reject Acorda’s MS drug Fampyra
22 June 2022 - NICE has announced its decision to reject Fampyra – also known as fampridine – for use ...
Posted by Michael Wonder on 16 Jun 2022
New treatment to increase the chances of a successful kidney transplant recommended by NICE
16 June 2022 - A new treatment that increases the chance of a successful kidney transplant has been recommended by ...